TL;DR: The Centers for Medicare & Medicaid Services modified NCD 222 governing Medicare coverage of home blood glucose monitors, effective March 7, 2026. Here's what billing teams need to know before the change takes effect.
CMS updated National Coverage Determination 222 (NCD 222), which controls Medicare reimbursement for home blood glucose monitoring devices billed under the Durable Medical Equipment benefit category. The modification clarifies coverage criteria for standard monitors and specially designed systems for patients with visual impairments. No specific HCPCS codes are listed in the policy document itself — a notable gap your billing team needs to account for when coding claims.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | Home Blood Glucose Monitors |
| Policy Code | NCD 222 |
| Change Type | Modified |
| Effective Date | March 7, 2026 |
| Impact Level | Medium |
| Specialties Affected | Endocrinology, Primary Care, Internal Medicine, Ophthalmology, DME Suppliers |
| Key Action | Audit your DME billing workflows for home glucose monitors before March 7, 2026 to confirm documentation meets the three-condition coverage criteria |
CMS Home Blood Glucose Monitor Coverage Criteria and Medical Necessity Requirements 2026
The central coverage question under NCD 222 is whether the device and the patient together meet three specific conditions. Miss any one of them and you're looking at a claim denial.
Here's the exact three-condition test CMS uses for standard home blood glucose monitors:
| # | Covered Indication |
|---|---|
| 1 | Diabetes diagnosis confirmed. The patient must have a documented diagnosis of diabetes. This is the floor — no diagnosis, no coverage, full stop. |
| 2 | Physician-documented training capability. The patient's physician must state that the patient is capable of being trained to use the specific device prescribed. If the patient cannot perform this function, a responsible caregiver can substitute — but only if the physician documents this arrangement in the medical record. That "properly documented by the patient's physician" language is doing a lot of work here, and it's the part most likely to create a claim denial if missing. |
| 3 | Home-use device, not clinical. The device must be designed for home use, not clinical settings. |
Supplies tied directly to the device — lancets, reagent strips, and other necessary consumables — are also covered for patients who meet these criteria. Document the supplies as part of the equipment order, not as a standalone claim.
The real issue with this coverage policy is condition two. In practice, plenty of billing teams get the diabetes diagnosis locked down and the home-use device confirmed, then let physician documentation of training capability slip. That's the one that comes back as a denial months later when a medical necessity audit hits.
CMS also addresses a distinct device category under NCD 222: blood glucose monitoring systems designed for patients with visual impairments. These systems include voice synthesizers, automatic timers, and specially configured supply arrangements. They're covered under the same three-condition framework as standard monitors, plus one additional requirement — the patient's physician must certify a visual impairment severe enough to require the special system.
These visually impaired patient systems are explicitly recognized as warranting a higher reimbursement amount than standard monitors. CMS instructs payers to separately identify claims for these devices and establish a separate reimbursement amount. If your team is billing for these systems, make sure claims are clearly distinguished from standard monitor claims — lumping them together leaves reimbursement on the table.
One thing CMS is equally clear about: reflectance colorimeter devices designed for clinical settings are not covered as DME for home use. The reason is straightforward — they require frequent professional recalibration, which makes them unsuitable for home use by definition. If a device description matches this profile, don't bill it under the home DME benefit.
Prior authorization requirements for home blood glucose monitors are not specified within NCD 222 itself. That determination sits with your Medicare Administrative Contractor (MAC). Check with your MAC before March 7, 2026 if you're uncertain about prior auth requirements in your region.
CMS Home Blood Glucose Monitor Exclusions and Non-Covered Indications
One exclusion is explicit and firm: clinical reflectance colorimeter devices are not covered as durable medical equipment for home use.
The policy's rationale is that these devices require frequent professional recalibration. They're designed for clinical environments where trained staff can maintain calibration integrity. Billing one of these under the home DME benefit will result in denial — and if it's a pattern, it creates audit exposure.
The coverage policy draws a clean line: home-use devices are covered (when criteria are met), clinical-grade devices are not. Make sure your DME suppliers and ordering physicians understand which side of that line a device sits on before the order goes in.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Standard home blood glucose monitor — patient with diabetes, documented training capability, home-use device | Covered | No specific codes listed in NCD 222 | All three coverage conditions must be met; physician documentation required |
| Supplies (lancets, reagent strips, etc.) for covered monitor | Covered | No specific codes listed in NCD 222 | Covered for patients for whom the device itself is indicated |
| Blood glucose monitoring system for visually impaired patients | Covered (higher reimbursement) | No specific codes listed in NCD 222 | Must meet all three standard conditions plus physician certification of visual impairment; bill separately from standard monitors |
| Clinical reflectance colorimeter device for home use | Not Covered | N/A | Requires frequent professional recalibration — not suitable for home use per CMS |
CMS Home Blood Glucose Monitor Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit your physician documentation process before March 7, 2026. Confirm that ordering physicians are explicitly documenting: (a) the diabetes diagnosis, (b) the patient's capability to be trained on the specific device, and (c) — if a caregiver is being trained instead — the reason the patient cannot self-manage. This third-party caregiver documentation is the most commonly missed element and a frequent source of post-payment audits. |
| 2 | Separate your claims for visually impaired patient systems from standard monitors. NCD 222 is explicit that these systems carry a higher reimbursement amount and must be billed on separate claims. If your team has been bundling them with standard monitor claims, that's a billing error you want to fix before March 7, 2026 — not after a MAC audit. |
| 3 | Confirm your device descriptions match "home use" not "clinical use." Before billing any glucose monitor under the DME benefit, verify that the device is manufactured and labeled for home use. If a supplier is providing a device that crosses into clinical-grade territory, coverage denial is automatic under NCD 222 — no exceptions. |
| 4 | Contact your MAC to clarify prior authorization requirements. NCD 222 doesn't set prior auth rules directly. Those are MAC-level determinations. If your billing team doesn't already have a clear protocol for which monitor claims require prior authorization in your region, get that answer from your MAC before the effective date. |
| 5 | Review your documentation templates for the physician certification language. The policy specifically requires the physician to certify a "visual impairment severe enough to require use of this special monitoring system" for the visually impaired category. Generic physician notes won't satisfy this requirement. Update your order templates to include this specific language if you service visually impaired diabetic patients. |
| 6 | Verify supply claims are linked to a covered monitor. Lancets and reagent strips are covered — but only for patients for whom the device itself is indicated. If a patient no longer meets coverage criteria for the monitor, the supply claims lose their coverage basis. Periodic eligibility re-checks on ongoing supply orders are good practice here. |
If your practice or DME supply operation has significant volume in diabetic monitoring equipment and you're uncertain how NCD 222's changes affect your specific billing mix, loop in your compliance officer before March 7, 2026.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Home Blood Glucose Monitors Under NCD 222
NCD 222 does not list specific CPT, HCPCS, or ICD-10 codes within the policy document itself. This is a meaningful gap for billing teams.
In practice, home blood glucose monitors and their supplies are billed using HCPCS Level II codes — your DME billing team or MAC can confirm the current applicable codes for standard monitors, visually impaired monitoring systems, and associated supplies. Do not assume code selection from this policy document alone.
Because no codes are specified in the policy data, the tables below are intentionally left without fabricated entries. Pulling incorrect codes from an NCD that doesn't specify them is a fast path to systematic denials.
Practical step: Pull your MAC's DME fee schedule and cross-reference your current HCPCS codes for glucose monitors against NCD 222's coverage criteria. If you're not sure which HCPCS codes map to the visually impaired system category, contact your MAC directly — the reimbursement differential makes this worth the call.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.